Spoken Alpha
Immunome Inc.
Immunome develops oncology therapies, including antibody-drug conjugates and other targeted cancer treatments. The company's pipeline includes varegacestat, an oral gamma secretase inhibitor for desmoid tumors with positive Phase 3 results, plus early-stage programs targeting ROR1, FAP, and other cancer-related proteins.
Immunome Inc is a Healthcare company operating in Biotechnology with a $2.71B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add IMNM, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMNM.
$ curl https://api.spokenalpha.com/v1/companies/IMNMFAQ
Spoken Alpha indexes IMNM's earnings call transcripts at https://spokenalpha.com/companies/IMNM. Each call links to attributed speakers and parsed analyst Q&A. Immunome Inc.'s own investor relations page is at https://investors.immunome.com/.
Immunome Inc. (IMNM) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.64 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-10 | $-0.65 | $-0.51 | -27.5% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.48 | $-0.59 | +19.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $-0.76 | $-0.57 | -33.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.65 | $-0.54 | -20.4% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-0.50 | $-0.50 | 0.0% | $4.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.52 | $-0.57 | +8.8% | $2.9M | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.84 | $-0.68 | -23.5% | $2.7M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.78 | $-0.58 | -34.5% | $2.9M | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.60 | $-0.40 | -50.0% | $2.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-2.51 | $-0.45 | -100.0% | $1.0M | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-4.22 | $-0.28 | -100.0% | $3.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.36 | $-0.17 | -100.0% | $3.6M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.46 | $-0.16 | -100.0% | $4.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-04 | $-0.35 | $0.59 | -100.0% | $2.4M | — | — | EODHD |
| Q4 FY2022 | 2023-03-15 | $-0.64 | $-0.67 | +4.5% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.75 | $-0.78 | +3.9% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-04 | $-0.74 | $-0.93 | +20.4% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.96 | $-0.69 | -39.1% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-27 | $-0.68 | $-0.81 | +16.1% | $0 | — | — | EODHD |
Source: EODHD. IMNM reported actuals as published; sparse fields render as —.